Magnetic nano capture agent with enhanced anion internal layer diffusion performance for removal of arsenic from human blood
Magnetic nano capture agent with enhanced anion internal layer diffusion performance for removal of arsenic from human blood
复制标题
具有增强阴离子内层扩散性能的磁性纳米捕获剂用于去除人体血液中的砷
DOI：
10.1016/j.apsusc.2018.11.135
复制
发表时间：
2019-03
影响因子：
6.7
通讯作者：
Bai Zhiming
中科院分区：
文献类型：
--
作者：
Guo Xueyi;Wang Weijia;Yang Ying;Tian Qinghua;Xiang Yang;Sun Yan;Bai Zhiming
基于磁性纳米捕获剂（MNCA）的磁分离可以高效、安全地去除血液中的重金属。它被认为是下一代重金属中毒的治疗方法。在这项工作中，我们报告了第一次使用MNCA去除砷（As）的血液中的高效率。通过货车德瓦尔斯力将油酸包裹的磁性氧化铁纳米粒子（MNP@OA）包裹在十六烷基三甲基溴化铵（CTAB）和牛血清白蛋白（BSA）之间，制备了具有柔性、非共价键和生物相容性的表面层MNCA。该表面层增强了砷阴离子从表面向结合位点的扩散，从而提高了MNCA的除砷性能。BSA和CTAB包合MNP@OA（MNP@CTAB-BSA）对As（III）和As（V）的吸附容量分别为131.00 mg g− 1和119.58 mg g−1。MNP@CTAB-BSA对As（III）和As（V）的去除率分别为89.02%和81.78%，As（III）和As（V）在血液中的残留浓度分别从400.00 μg L− 1降至43.93 μg L− 1和72.88 μg L−1。所合成的MNP@CTAB-BSA显示出优异的生物相容性。在操作条件下，MNP@CTAB-BSA仅引起0.80%的溶血和1.64%的血浆蛋白吸附，外周血单个核细胞（PBMCs）的细胞活力大于95.53%。本研究为砷中毒的治疗提供了一种快速、安全、有效的方法。
Magnetic nano capture agent (MNCA)-based magnetic separation can remove heavy metals from blood efficiently and safely. It has been considered as the next-generation therapy for heavy metal intoxication. In this work, we report the first use of MNCA to remove arsenic (As) with high efficiency from blood. MNCA with a flexible, non-covalent and biocompatible surface layer has been synthesized by packaging cetyltrimethylammonium bromide (CTAB) and bovine serum albumin (BSA) together with oleic acid coated magnetic iron oxide nanoparticles (MNP@OA) via Van der Waals force. This surface layer enhances arsenic anion diffusion from the surface to the binding sites, leading to increased arsenic removal performance of MNCA. The adsorption capacities of BSA and CTAB enfolded MNP@OA (MNP@CTAB-BSA) for As (III) and As (V) are 131.00 mg g−1and 119.58 mg g−1, respectively. 89.02% of As (III) and 81.78% of As (V) are removed from blood using MNP@CTAB-BSA, and the residual concentrations of As (III) and As (V) in blood decrease from 400.00 μg L−1to 43.93 μg L−1and 72.88 μg L−1, respectively. The as-synthesized MNP@CTAB-BSA shows excellent biocompatibility. Under operation condition, only 0.80% of hemolysis and 1.64% of plasma protein adsorption are induced by MNP@CTAB-BSA, and the cell viability of peripheral blood mononuclear cells (PBMCs) is more than 95.53%. This study paves a fast, safe and effective way for arsenic intoxication therapy.
登录
查看更多内容
影响因子：
82.9
作者：
Kang, Joo H.;Super, Michael;Ingber, Donald E.
通讯作者：
Ingber, Donald E.
影响因子：
56.9
作者：
Zhang, Xiao-Wei;Yan, Xiao-Jing;Chen, Zhu
通讯作者：
Chen, Zhu
影响因子：
56.9
作者：
Yavuz, Cafer T.;Mayo, J. T.;Colvin, Vicki L.
通讯作者：
Colvin, Vicki L.
影响因子：
9.5
作者：
Bohmer, Nils;Demarmels, Nino;Herrmann, Inge K.
通讯作者：
Herrmann, Inge K.
影响因子：
17.1
作者：
Chandra, Vimlesh;Park, Jaesung;Kim, Kwang S.
通讯作者：
Kim, Kwang S.